We are live on ! Find out more
AMLX icon

Amylyx Pharmaceuticals
AMLX

110 hedge funds and large institutions have $141M invested in Amylyx Pharmaceuticals in 2024 Q3 according to their latest regulatory filings, with 22 funds opening new positions, 32 increasing their positions, 36 reducing their positions, and 31 closing their positions.

New
Increased
Maintained
Reduced
Closed

70% more capital invested

Capital invested by funds: $82.9M → $141M (+$57.8M)

0.34% less ownership

Funds ownership: 64.16% → 63.82% (-0.34%)

8% less funds holding

Funds holding: 119 → 110 (-9)

11% less repeat investments, than reductions

Existing positions increased: 32 | Existing positions reduced: 36

29% less first-time investments, than exits

New positions opened: 22 | Existing positions closed: 31

74% less call options, than puts

Call options by funds: $796K | Put options by funds: $3.04M

Holders
110
Holders Change
-9
Holders Change %
-7.56%
% of All Funds
1.58%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
22
Increased
32
Reduced
36
Closed
31
Calls
$796K
Puts
$3.04M
Net Calls
-$2.25M
Net Calls Change
+$1.22M

Top Buyers

Rank Fund Capital Flow
1
TCM
TCG Crossover Management
California
+$10.4M
2
PA
Perceptive Advisors
New York
+$4.78M
3
Aberdeen Group
Aberdeen Group
United Kingdom
+$4.17M
4
NCM
Nantahala Capital Management
Connecticut
+$3.16M
5
AWG
Alpha Wave Global
New York
+$1.5M

Top Sellers

Rank Fund Capital Flow
1
AQR Capital Management
AQR Capital Management
Connecticut
-$6.05M
2
BC
Boxer Capital
California
-$2.85M
3
Vanguard Group
Vanguard Group
Pennsylvania
-$2.55M
4
Millennium Management
Millennium Management
New York
-$2.42M
5
Goldman Sachs
Goldman Sachs
New York
-$2.24M
Name Holding Trade Value Shares
Change 		Change in
Stake
Susquehanna International Group
26
Susquehanna International Group
Pennsylvania
$1.32M -$89.6K -39,881 -9%
Two Sigma Investments
27
Two Sigma Investments
New York
$1.19M -$2.09M -930,601 -72%
Jane Street
28
Jane Street
New York
$1.12M -$330K -146,934 -30%
GTC
29
Ghost Tree Capital
New York
$1.05M +$731K +325,000 New
Two Sigma Advisers
30
Two Sigma Advisers
New York
$1M -$1.9M -844,700 -73%
Charles Schwab
31
Charles Schwab
California
$979K -$493K -219,349 -42%
Marshall Wace
32
Marshall Wace
United Kingdom
$920K +$638K +283,986 New
IC
33
Ikarian Capital
Texas
$890K – – –
Renaissance Technologies
34
Renaissance Technologies
New York
$881K -$1.21M -539,688 -67%
AC
35
Aldebaran Capital
Indiana
$874K – – –
UBS Group
36
UBS Group
Switzerland
$742K +$447K +198,937 +660%
First Trust Advisors
37
First Trust Advisors
Illinois
$718K +$186K +82,529 +59%
Fidelity Investments
38
Fidelity Investments
Massachusetts
$716K +$370K +164,622 +292%
ACM
39
ADAR1 Capital Management
Texas
$716K +$255K +113,600 +106%
PAM
40
Panagora Asset Management
Massachusetts
$611K – – –
Federated Hermes
41
Federated Hermes
Pennsylvania
$604K +$16.9K +7,512 +4%
Qube Research & Technologies (QRT)
42
Qube Research & Technologies (QRT)
United Kingdom
$596K -$1.36M -605,233 -77%
SSA
43
Schonfeld Strategic Advisors
New York
$539K +$326K +144,829 +671%
State Street
44
State Street
Massachusetts
$502K – – –
JP Morgan Chase
45
JP Morgan Chase
New York
$455K +$187K +83,048 +144%
Bank of Montreal
46
Bank of Montreal
Ontario, Canada
$442K +$86K +38,263 +36%
Man Group
47
Man Group
United Kingdom
$424K +$33.1K +14,733 +13%
BCM
48
Bridgeway Capital Management
Texas
$421K – – –
Group One Trading
49
Group One Trading
Illinois
$419K -$360K -159,991 -55%
SC
50
Shay Capital
New York
$380K +$264K +117,328 New
1
2
3 4 5

AMLX Hedge Fund Activity: Q3 2024 in Review

110 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Amylyx Pharmaceuticals (AMLX) for Q3 2024, worth a combined $141M — up 70% from $82.9M a quarter earlier.

Sellers outnumbered buyers: 31 funds closed out of AMLX and 22 opened new positions — a net loss of 9 holders — while 36 trimmed existing stakes and 32 added.

The largest buyer was TCG Crossover Management, opening a new position worth an estimated $10.4M. The largest seller was AQR Capital Management, cutting an estimated $6.05M.

  • 110 institutional investors held Amylyx Pharmaceuticals (AMLX) as of Q3 2024, down from 119 in Q2 2024.
  • Funds reported $141M of Amylyx Pharmaceuticals stock for Q3 2024, up 70% quarter-over-quarter.
  • 22 funds opened new Amylyx Pharmaceuticals positions in Q3 2024 and 31 closed out, a net change of -9 holders.
  • The largest Amylyx Pharmaceuticals buyer in Q3 2024 was TCG Crossover Management, an estimated $10.4M added.
  • The largest Amylyx Pharmaceuticals seller in Q3 2024 was AQR Capital Management, an estimated $6.05M sold.

Based on aggregated 13F filings for Q3 2024.